Tirzepatide targets both the GLP-1 receptor as well as that of the GIP, which gives it a metabolic boosting factor that creates a better modality and efficiency for cell energy production
EMA refused 2017) [11]
Gastrointestinal Adverse Events GI AEs are the most frequently reported side effects of GLP-1 RAs and, although typically mild, moderate, and transient, they remain the primary reason for treatment discontinuation among individuals with obesity receiving semaglutide [13, 27, 38, 40,41,42,43,44,45,46, 52]
Potential for significant weight loss for many individuals
These are complemented by moisturising and skin-conditioning ingredients such as panthenol and ceramides, helping the formula support hydration and skin comfort while working towards a clearer, more radiant appearance
No shipping to Austria